Evolving Treatment Options for Lung Cancer

Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001.

Authors

Daniel Morgensztern¹, Roy S Herbst²

Affiliations

¹ Thoracic Oncology Program, Washington University, 660 South Euclid Avenue, Box 8056, St Louis, MO 63110, USA. Electronic address: dmorgens@wustl.edu.
² Yale School of Medicine, Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT 06519, USA. Electronic address: Roy.herbst@yale.edu.

PMID: 27912837
DOI: 10.1016/j.hoc.2016.09.001

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Biomarkers, Tumor / antagonists & inhibitors
Biomarkers, Tumor / genetics
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Carcinoma, Small Cell / genetics
Carcinoma, Small Cell / pathology
Carcinoma, Small Cell / therapy*
Humans
Immunotherapy / methods
Immunotherapy / trends
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends

Substances

Biomarkers, Tumor